Literature DB >> 7665869

Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation.

P H Bernard1, B Le Bail, M Cransac, M G Barcina, J Carles, C Balabaud, P Bioulac-Sage.   

Abstract

We report the case of a 30-year-old male patient suffering from what was initially thought to be end-stage cryptogenic cirrhosis with portal hypertension and liver failure, who underwent liver transplantation. Histological examination of the surgical specimen showed incomplete septal cirrhosis. At the age of 17 this patient had presented pancytopenia and splenomegaly, which were treated by splenectomy. The surgeon discovered portal hypertension. Re-examination of the wedge liver biopsy taken at this time revealed features of idiopathic portal hypertension. This case clearly shows that incomplete septal cirrhosis may be a late manifestation of idiopathic portal hypertension. The presence of sinusoidal dilatation and peliosis as well as early evidence of fibrosis which are already visible on the initial biopsy and are still present on the late specimen, are indirect evidence of a continuous process which ultimately led to incomplete cirrhosis with liver failure.

Entities:  

Mesh:

Year:  1995        PMID: 7665869     DOI: 10.1016/0168-8278(95)80115-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Noncirrhotic portal fibrosis: a rare cause of end-stage liver disease requiring liver transplantation.

Authors:  Sunil Taneja; Yogesh Chawla; Radha K Dhiman
Journal:  Hepatol Int       Date:  2011-09-03       Impact factor: 6.047

2.  Implications of portal vein thrombosis after splenectomy for patients with idiopathic portal hypertension.

Authors:  Teijiro Hirashita; Masayuki Ohta; Seiichiro Kai; Takashi Masuda; Hidetoshi Eguchi; Yukio Iwashita; Tadashi Ogawa; Seigo Kitano
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

3.  Hepatobiliary quiz 11 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-09

4.  Noncirrhotic intrahepatic portal hypertension: towards a unifying definition and etiology.

Authors:  B S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2014-05-31

Review 5.  Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options.

Authors:  Ashish Goel; Joshua E Elias; Chundamannil E Eapen; Banumathi Ramakrishna; Elwyn Elias
Journal:  J Clin Exp Hepatol       Date:  2014-07-28

6.  Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis.

Authors:  Aydin Seref Köksal; Seyfettin Köklü; Mehmet Ibiş; Mustafa Balci; Bahattin Ciçek; Nurgül Saşmaz; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

7.  Familial occurrence of nodular regenerative hyperplasia of the liver: a report on three families.

Authors:  J Dumortier; O Boillot; M Chevallier; F Berger; P Potier; P J Valette; P Paliard; J Y Scoazec
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

8.  Life-threatening hypersplenism due to idiopathic portal hypertension in early childhood: case report and review of the literature.

Authors:  Jan Däbritz; Jennifer Worch; Ulrike Materna; Bernward Koch; Gabriele Koehler; Christina Duck; Michael C Frühwald; Dirk Foell
Journal:  BMC Gastroenterol       Date:  2010-10-20       Impact factor: 3.067

9.  Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension.

Authors:  Kadim Bayan; Yekta Tüzün; Serif Yilmaz; Naime Canoruc; Mehmet Dursun
Journal:  J Thromb Thrombolysis       Date:  2008-08-07       Impact factor: 2.300

10.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.

Authors:  S Hillaire; E Bonte; M-H Denninger; N Casadevall; J-F Cadranel; D Lebrec; D Valla; C Degott
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.